Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H


Primary Symbol: CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Post by HighSkies2019on Apr 15, 2020 8:46am
107 Views
Post# 30910775

More to come for sure

More to come for sureEdrose give it a rest...I was feeling concerned not hearing from you a couple of days ... but now I just want to do to take your broken battery out...your on constant repeat with nothing of value... I still think you could still be the a.k.a penny ... we still have till 1st quarter report or deal which ever comes first to pay talent ... as for the L.O.I. acquisition to stero was a tactic play imo ... there was no penalty for cancelling ...and no rumbling about no payment because same parties involved from all 3 entities... they will all be rewarded if a deal happens ... and as stated that if Kly fails everything goes back to Talent again all same players ... mar 27 nr by Dr Sari Prutchi Sagiv...maybe this is what she was to present at the big medical conference ... again more positive in Kly's direction ... I anticipate a deal of some sort
<< Previous
Bullboard Posts
Next >>